394 related articles for article (PubMed ID: 27227654)
21. Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis.
Hadi I; Schummer A; Dreyling M; Eze C; Bodensohn R; Roengvoraphoj O; Belka C; Li M
Sci Rep; 2021 Nov; 11(1):22586. PubMed ID: 34799601
[TBL] [Abstract][Full Text] [Related]
22. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
[TBL] [Abstract][Full Text] [Related]
23. Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging.
Song EJ; Torok J; Wu Y; Chino J; Prosnitz LR; Beaven AW; Kelsey CR
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):145-151. PubMed ID: 29358045
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
25. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.
Lee SJ; Suh CW; Lee SI; Kim WS; Lee WS; Kim HJ; Choi CW; Kim JS; Shin HJ;
Korean J Intern Med; 2014 May; 29(3):352-60. PubMed ID: 24851070
[TBL] [Abstract][Full Text] [Related]
27. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
28. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
[TBL] [Abstract][Full Text] [Related]
29. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
30. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
[TBL] [Abstract][Full Text] [Related]
31. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
Milgrom SA; Pinnix CC; Chuang H; Oki Y; Akhtari M; Mawlawi O; Garg N; Gunther JR; Reddy JP; Smith GL; Rohren E; Hagemeister FB; Lee HJ; Fayad LE; Dong W; Osborne EM; Abou Yehia Z; Fanale M; Dabaja BS
Br J Haematol; 2017 Nov; 179(3):488-496. PubMed ID: 28832956
[TBL] [Abstract][Full Text] [Related]
32. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
[TBL] [Abstract][Full Text] [Related]
33. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of treatment for spinal cord compression due to primary non-Hodgkin lymphoma.
Tang Y; Yang X; Xiao J; Liu K; Yan W; Song D; Qu J; Ma J; Wan W
Spine J; 2013 Jun; 13(6):641-50. PubMed ID: 23337542
[TBL] [Abstract][Full Text] [Related]
35. Treatment of breast cancer during pregnancy: an observational study.
Loibl S; Han SN; von Minckwitz G; Bontenbal M; Ring A; Giermek J; Fehm T; Van Calsteren K; Linn SC; Schlehe B; Gziri MM; Westenend PJ; Müller V; Heyns L; Rack B; Van Calster B; Harbeck N; Lenhard M; Halaska MJ; Kaufmann M; Nekljudova V; Amant F
Lancet Oncol; 2012 Sep; 13(9):887-96. PubMed ID: 22902483
[TBL] [Abstract][Full Text] [Related]
36. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
37. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
38. [A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma].
Tao Y; Kang S; Zhou L; Shi Y; Li Y; Sun Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):466-71. PubMed ID: 26463153
[TBL] [Abstract][Full Text] [Related]
39. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
[TBL] [Abstract][Full Text] [Related]
40. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.
Pinnix CC; Milgrom SA; Cheah CY; Gunther JR; Ludmir EB; Wogan CF; Nastoupil LJ; Neelapu SS; Westin J; Lee HJ; Iyer SP; Steiner RE; Fayad LE; Fowler NH; Wang ML; Samaniego F; Rodriguez MA; Rich AE; Medeiros LJ; Dabaja BS
Blood Adv; 2019 May; 3(9):1356-1367. PubMed ID: 31036721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
